Michal Hrnčiarik

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Petra Zemanová et al. · Anticancer Research · 2020 · 86 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Jana Skřičková et al. · Anticancer Research · 2018 · 41 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype

Vladimír Koblížek, M Tomšová, Eva Čermáková et al. · Rhinology Journal · 2011 · 31 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives

Petra Fikrová, Rudolf Štětina, Michal Hrnčiarik et al. · Oncology Reports · 2013 · 23 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

Ondřej Fiala, Miloš Pešek, Jana Skřičková et al. · Tumor Biology · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacology +13